Project description
Novel therapeutic targets against colorectal cancer
Immune system activation constitutes a promising approach for the treatment of cancer. However, it has not been possible to identify cancer-specific targets for therapeutic and diagnostic purposes. The EU-funded InnoTACA project aims to identify tumour-associated carbohydrate antigens (TACA) in colorectal cancer (CRC), which currently has limited treatment options. Researchers envision the identification of molecules that will serve as leads for the development of safer and more cost-effective immunotherapies applicable to even advanced unresectable CRC. Moreover, these targets can be used to predict the clinical outcome during cancer management and treatment.
Objective
CellmAbs is a recent but fast growing biopharmaceutical spinoff dedicated to the development of immuno-oncology agents that target only cancer cells, promoting the activation of the immune system and inhibiting growth of cancer in both early and late stages.
In spite of many advances in diagnostic and treatment development, many cancers still have no targeted therapy or have limited or toxic treatment options. Early detection is crucial to optimize treatment and substantially reduce incidence and mortality. In spite of the advent of new and improved genomic and proteomic technologies, it has not been possible to identify cancer-specific therapeutic targets or molecules that are able to reliably and accurately predict outcomes during cancer management and treatment. Cancers such as colorectal cancer (CRC) have very poor standard of care and thus own an unmet need for reliable and specific targets. The discovery of tumour associate carbohydrate antigens (TACA) is very promising but is still very insipient due to lack of experts, knowledge and technology on the field.
InnoTACA will address several unmet needs by presenting the grounds for hiring an Innovation Associate with relevant expertise and experience on groundbreaking technology to innovate TACA discovery to apply in cancer theranostic, combining high-quality transferable-skill training with excellent scientific training in glycomics. InnoTACA addresses the CellmAbs need of identifying highly specific TACAs, which would serve as a lead for the development of safer and more cost-effective immunotherapies, even for advanced unresectable CRC.
The InnoTACA Associate and such immunotherapies will provide CellmAbs with improved products to capitalize and compete with current healthcare business and it will allow CellmAbs to connect with other high-tech SMEs focused in pharmaceutical and medical development, and partners with strong translational clinical and research backgrounds.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology demography mortality
- medical and health sciences clinical medicine oncology colorectal cancer
- natural sciences biological sciences biochemistry biomolecules carbohydrates
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.2.2. - Enhancing the innovation capacity of SMEs
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
CSA - Coordination and support action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-INNOSUP-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2510-216 Leiria
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.